<DOC>
	<DOCNO>NCT00199121</DOCNO>
	<brief_summary>The purpose study evaluate antiviral effect durability antiviral response ( HIV-1 RNA PCR ) safety triple NtRTI/NsRTI therapy antiretroviral naive patient . Patients receive TDF plus FTC plus AZT least 48 week . Further objective evaluate resistance pathway fail patient treat TDF/FTC/AZT evaluate treatment strategy spar PIs NNRTIs later treatment .</brief_summary>
	<brief_title>A Pilot Study Triple NtRTI/NsRTI Therapy Antiretroviral Naive HIV-1 Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>18 year old HIV1 positive antiretroviral treatment naive one CD4 count &gt; 200/ul within 14d prior study drug administration one HIV1 RNA PCR value &gt; 5000 &lt; 100.000 cop/ml within 14d prior study drug administration woman child bear potential : negative serum pregnancy test within 14d study ability understand provide write informed consent overall stable disease absence clinical sign lipodystrophy alcohol illicit drug use malabsorption syndrome gastrointestinal dysfunction clinically relevant pancreatitis/hepatitis within last 6 month receive investigational drug abnormal hemoglobin , neutrophil , platelet , AST/ALT , pancreatic amylase , creatinine clearance , total bilirubine level within 14d prior study pregnancy/breastfeeding radiation therapy cytotoxic chemotherapeutic agent within 30d study prior antiretroviral therapy time , investigational antiretrovirals trial time , HIV vaccine within 90d prior study immunomodulating agent serious medical condition ( diabetes , congestive heart failure , cardiomyopathy , cardiac dysfunction ) active diagnosis AIDS ( except cutaneous Kaposi Sarcoma ) foscarnet therapy agent document activity HIV1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2005</verification_date>
</DOC>